SYNDAX PHARMACEUTICALS (SNDX) Covered Calls

You can sell covered calls on SYNDAX PHARMACEUTICALS to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for SNDX (prices last updated Fri 4:16 PM ET):

SYNDAX PHARMACEUTICALS (SNDX) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
6.39 -0.17 6.01 7.20 208K - 0.2B
Covered Calls For SYNDAX PHARMACEUTICALS (SNDX)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Oct 19 7.5 0.00 7.20 0.0% 0.0%
Nov 16 7.5 0.05 7.15 0.7% 7.1%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH, Genentech, Inc., Merck KGaA, Pfizer, and AstraZeneca; collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.